Señales en vivo de IDIA.SW | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 11:31):

Stats
Volumen de hoy	497 043
Volumen promedio	1.18M
Capitalización de mercado	368.81M
EPS	CHF0 ( 2024-02-05 )
Próxima fecha de ganancias	( CHF-0.810 ) 2024-05-20
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-0.930
ATR14	CHF0.0180 (0.92%)

Volumen Correlación

Largo: 0.12 (neutral)

Corto: 0.09 (neutral)

Signal:(49.239) Neutral

Idorsia Ltd Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Idorsia Ltd Correlación - Moneda/Commodity

0.33
( neutral )

0.40
( neutral )

0.00
( neutral )

0.27
( neutral )

0.40
( neutral )

-0.38
( neutral )

Idorsia Ltd Finanzas

Annual	2023
Ingresos:	CHF0
Beneficio Bruto:	CHF0 (0.00 %)
EPS:	CHF0

FY	2023
Ingresos:	CHF0
Beneficio Bruto:	CHF0 (0.00 %)
EPS:	CHF0

FY	2022
Ingresos:	CHF97.10M
Beneficio Bruto:	CHF90.84M (93.55 %)
EPS:	CHF-4.67

FY	2021
Ingresos:	CHF35.35M
Beneficio Bruto:	CHF0.00 (0.00 %)
EPS:	CHF-3.77

Financial Reports:

No articles found.

Idorsia Ltd

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.